InVivo Therapeutics Holdings Corp. (NVIV) today announced that
the company was featured in a Bloomberg Businessweek article on
Thursday, October 1.
Michelle Fay Cortez, health and science reporter for Bloomberg for over
10 years, interviewed key members of the InVivo team, including
co-founder Robert Langer and Chief Executive Officer and Chairman Mark
Perrin. Dom Coric, M.D., Principal Investigator and neurosurgeon who
performed the second- and third-ever Neuro-Spinal Scaffold
implantation procedure was also interviewed.
“Having such a well-respected media outlet cover our novel therapeutic
approach to spinal cord injury is rewarding. This article explains the
many facets of the InVivo story and we’re pleased that it highlights our
scientific progress and our commitment to patients with spinal cord
injuries,” said Mr. Perrin.
To view the article, please visit: http://www.bloomberg.com/news/articles/2015-10-01/early-promise-for-neuro-spinal-scaffold-a-new-paralysis-treatment
Founded in 1929, Bloomberg Businessweek is a trusted market
leader with a global circulation of over 980,000 each week and is
available in more than 150 countries. The magazine’s website receives
more than 7.5 million monthly views.
About the Neuro-Spinal Scaffold™
Following an acute spinal cord injury, the biodegradable Neuro-Spinal
Scaffold is surgically implanted at the epicenter of the wound and
is designed to act as a physical substrate for nerve sprouting.
Appositional healing to spare spinal cord tissue, decreased
post-traumatic cyst formation, and decreased spinal cord tissue pressure
have been demonstrated in preclinical models of spinal cord contusion
injury. The Neuro-Spinal Scaffold, an investigational device, has
received a Humanitarian Use Device (HUD) designation and is currently
being studied in an Investigational Device Exemption (IDE) pilot study
for the treatment of patients with complete (AIS A) traumatic acute
spinal cord injury.
About InVivo Therapeutics
InVivo Therapeutics Holdings Corp. is a research and clinical-stage
biomaterials and biotechnology company with a focus on treatment of
spinal cord injuries. The company was founded in 2005 with proprietary
technology co-invented by Robert Langer, Sc.D., Professor at
Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who
then was at Boston Children’s Hospital and who now is affiliated with
Massachusetts General Hospital. In 2011, the company earned the David S.
Apple Award from the American Spinal Injury Association for its
outstanding contribution to spinal cord injury medicine. In 2015, the
company’s investigational Neuro-Spinal Scaffold received the 2015
Becker’s Healthcare Spine Device Award. The publicly-traded company is
headquartered in Cambridge, MA. For more details, visit www.invivotherapeutics.com.
Safe Harbor Statement
Any statements contained in this press release that do not describe
historical facts may constitute forward-looking statements within the
meaning of the federal securities laws. These statements can be
identified by words such as "believe," "anticipate," "intend,"
"estimate," "will," "may," "should," "expect,"
“designed to,” “potentially,” and similar expressions, and include
statements regarding the expected benefits, efficacy and future
clinical outcomes of the company’s Neuro-Spinal Scaffold, its clinical
and commercialization timeline and the potential size of the market
addressed by the company’s proposed products. Any forward-looking
statements contained herein are based on current expectations, and are
subject to a number of risks and uncertainties. Factors that could cause
actual future results to differ materially from current expectations
include, but are not limited to, risks and uncertainties relating to the
company’s ability to successfully open additional clinical sites for
enrollment and to enroll additional patients; the timing of the
Institutional Review Board process; the company’s ability to obtain FDA
approval to modify its pilot trial protocol or to conduct a future
study; the company’s ability to commercialize its products; the
company’s ability to develop, market and sell products based on its
technology; the expected benefits and efficacy of the company’s products
and technology in connection with the treatment of spinal cord injuries;
the availability of substantial additional funding for the company to
continue its operations and to conduct research and development,
clinical studies and future product commercialization; and other risks
associated with the company’s business, research, product development,
regulatory approval, marketing and distribution plans and strategies
identified and described in more detail in the company’s Annual Report
on Form 10-K for the year ended December 31, 2014, and its other filings
with the SEC, including the company’s Form 10-Qs and current reports on
Form 8-K. The company does not undertake to update these forward-looking
statements.
![](http://cts.businesswire.com/ct/CT?id=bwnews&sty=20151002005142r1&sid=ntxv4&distro=nx&lang=en)
View source version on businesswire.com: http://www.businesswire.com/news/home/20151002005142/en/
Copyright Business Wire 2015